Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : anika research(anik) -- Ignore unavailable to you. Want to Upgrade?

To: Lou Cifer who wrote (120)	5/26/1998 3:24:00 PM
From: Eduardo Canto	Read Replies (4) \| Respond to of 328

Mr. Cifer: VIRS has four products in ph I and II trials: MKC-442, Alanosine,FTC , and DMP-450. Alanosine is for the treatment of cancer and the other three are for AIDS. I try to invest only in companies with products in or past phase III. I have learned this lesson the hard way. Nevertheless, the products look promising. With the fast progress being made in HIV therapy it is hard to predict how VIRS'products will be used. MKC-442 the company's most advanced product has the distinctive feature of achieving 100% penetration into the brain (CNS). If you like to speculate, chances are that companies with anti-HIV products will appreciate in value as we near the date of the this year's World AIDS Conference in late June. There is a good review of the current state of HIV therapy as part of a review of VRTX at: medicinvestor.com Best, EC